BRCA1‐deficient cancers are highly sensitive to chemotherapeutic agents.44, 45 In our study, BRCA1 was rapidly activated upon RD‐N treatment, followed by significant down‐regulation after 12 hours exposure, indicating the involvement of BRCA1 in RD‐N‐mediated DNA damage. Here, BRCA1 is linked to cancer.